Actively Recruiting
Optimizing HIV Prevention for Highly Vulnerable Methamphetamine-using Sexual Minority Men
Led by Florida International University · Updated on 2026-05-07
400
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of contingency management (CM) alone versus CM combined with motivational interviewing (MI) in helping individuals enter or re-enter the HIV prevention or care continuum. This hybrid type I randomized controlled trial focuses on highly vulnerable methamphetamine-using sexual minority men. The study aims to improve initiation of pre-exposure prophylaxis (PrEP) or anti-retroviral therapy (ART) among 400 participants. Participants are randomly assigned to one of two groups: CM alone, which provides financial incentives for starting HIV prevention or care and filling prescriptions, or MI combined with CM, which adds two telehealth counseling sessions focused on motivation and risk behavior reduction. Incentives of $50 each are offered for initiating care and for filling a PrEP or ART prescription within three months after randomization. Both interventions are delivered remotely via telehealth. During the 12-month study period, participants complete monthly follow-up assessments to evaluate prescription filling verified by digital photos. Researchers also collect self-reports on clinical evaluations, methamphetamine and other substance use severity, and condomless anal sex behaviors. The main outcome is the proportion of participants with verified PrEP or ART use at 12 months. Secondary outcomes include timing of prescription use and various behavioral measures related to HIV risk and substance use.
CONDITIONS
Brief Title
PrEP Readiness Interventions for Sustained Motivation (PRISM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Assigned male at birth
- Self-reported methamphetamine use in the past 3 months
- HIV-negative or unknown serostatus at baseline
- Has not filled a PrEP prescription in the past 6 months
You will not qualify if you...
- Unwilling or unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 3 months
Participants receive behavioral interventions including Motivational Interviewing sessions and Contingency Management incentives aimed at increasing motivation and supporting PrEP or HIV care initiation.
2 counseling sessions and periodic contact for incentive management over 3 months
Duration - Up to 12 months after treatment
Participants are monitored for PrEP or ART use and risk behaviors for up to 12 months after treatment to assess sustained motivation and prevention outcomes.
Periodic assessments during follow-up visits
Trial Site Locations
Total: 1 location
1
Florida International University
Miami, Florida, United States, 33199
Actively Recruiting
Research Team
A
Adam Carrico Professor, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here